Product nameCBL overexpression 293T lysate (whole cell)
ab94206 is a 293T cell transfected lysate in which Human CBL has been transiently over-expressed using a pCMV-CBL plasmid. The lysate is provided in 1 x Sample Buffer. Note: For more details about how the transfected lysate was prepared view preparation notes
Tested applicationsSuitable for: WBmore details
Storage instructionsShipped on dry ice. Upon delivery aliquot and store at -20ºC. Avoid freeze / thaw cycles.
Storage bufferpH: 6.80
Constituent: 100% 1x Sample Buffer
Concentration information loading...
- Cell Biology
- Proteolysis / Ubiquitin
- Proteasome / Ubiquitin
- Ubiquitin E3 Enzymes
- RING Finger E3 Ligase
- Signal Transduction
- Signaling Pathway
- Nuclear Signaling
- Nuclear Hormone Receptors
- Epigenetics and Nuclear Signaling
- Nuclear Signaling Pathways
- Nuclear Receptors
BackgroundCBL: Adapter protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling. Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation. Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis. Essential for osteoclastic bone resorption. The 'Tyr-731' phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. Pathway:protein ubiquitination. This protein is involved in the pathway protein ubiquitination, which is part of Protein modification. CBLB: E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. Slightly promotes SRC ubiquitination. May be involved in EGFR ubiquitination and internalization. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. Pathway: protein ubiquitination. This protein is involved in the pathway protein ubiquitination, which is part of Protein modification.
Our Abpromise guarantee covers the use of ab94206 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent dilution.|
ab94206 at 15µg/lane on an SDS-PAGE gel.
All lanes : Anti-CBL antibody (ab89529) at 1/500 dilution
Lane 1 :
CBL overexpression 293T lysate (whole cell) (ab94206)
Lane 2 : 293T non-transfected lysate
Lysates/proteins at 25 µg per lane.
All lanes : Goat Anti-mouse IgG (H and L) HRP conjugated at 1/2500 dilution
ab94206 has not yet been referenced specifically in any publications.